What is the endocannabinoid system (ECS)?

The system is textbook. The sales pitch is the stretch. Knowing that the ECS helps regulate sleep and mood is one fact; knowing whether a particular gummy moves either of them is another, and a far shakier one. That second kind of claim, that a cannabinoid improves a health outcome through the ECS, rests on thin evidence, mostly cells and mice, so CBG Atlas credits it to whoever makes it, limits attached, and it is the one worth checking before it reaches a label. The grades run from strongest to weakest: the six-rung evidence ladder, and topics not yet catalogued carry Catalogue in progress. None of it is medical or legal advice.

Sources: the CBG Atlas verified registry. Cascio 2010 and De Petrocellis 2011 describe CBG's mechanism in vitro, and Borrelli 2013 is a mouse study. Editorial stance: we report, we do not affirm.

What the ECS is and what it does

Physiologists have a word for the job: homeostasis, holding internal conditions steady while everything outside shifts. The ECS does its share by adjusting other body systems, and its core machinery is well mapped. Established

Three components do the work:

• Receptors: CB₁ and CB₂. Both are G-protein-coupled receptors on the surface of cells throughout the body, the locks that cannabinoid signals fit.
• Endocannabinoids: anandamide and 2-AG. The body's own cannabinoids are lipid messengers, and cells make them only when a signal is called for. They are assembled on demand from membrane fats, released, and cleared quickly.
• Enzymes that make and break them. Synthesizing enzymes assemble anandamide and 2-AG as they are needed. Degrading enzymes switch the signal off just as fast: chiefly FAAH, which breaks down anandamide, and MAGL, which breaks down 2-AG.

Think of a dimmer rather than a light switch. In the nervous system the ECS often signals backwards, a pattern called retrograde signaling, in which the receiving neuron releases endocannabinoids that travel back to the sending neuron and turn its output up or down. Through that tuning the ECS is understood to influence appetite, mood, pain signaling, sleep, memory and immune responses, keeping each within range, and its part in regulating them is Established physiology.

A dimmer is only as good as the hand on it, though. Whether any product has a steady hand on this one is a separate question, and the evidence for it is far thinner.

CB1 vs CB2: where each receptor sits

The two receptors are told apart by address. CB₁ clusters in the brain and nervous system, CB₂ in immune cells and peripheral tissues. Both are Established parts of the ECS, and the split explains a good deal about how cannabinoids behave.

• CB₁, the nervous-system receptor. CB₁ ranks among the most abundant receptors of its type in the brain, densest in the regions that govern memory, movement, emotion and appetite, and it sits on peripheral nerves too. THC activates CB₁, which is why THC intoxicates. A compound that blocks CB₁, as CBG does in laboratory studies, doesn't get anyone high.
• CB₂, the immune and peripheral receptor. CB₂ lives mostly on immune cells and in peripheral tissues such as the spleen and gut. The healthy adult brain has little of it, though levels can rise where there is inflammation. Its business is immune signaling, and intoxication lies outside it.

How phytocannabinoids like CBG interact with it

Which brings us to the plant. The cannabinoids cannabis makes, the phytocannabinoids, push the ECS in different directions, and CBG reaches well beyond it. THC is a partial agonist at CB₁ and intoxicates. CBG, in laboratory studies, does the reverse and blocks the receptor, one reason it doesn't. Demonstrated · in vitro

In laboratory (in vitro) studies, CBG's profile looks like this:

• CB₁, the ECS receptor: a blocker. CBG is a CB₁ receptor competitive antagonist (Cascio 2010). It occupies the receptor without switching it on, roughly the opposite of what THC does.
• TRP ion channels: a modulator. CBG activates and then desensitizes TRPV1 and TRPV2, and it blocks TRPM8 (De Petrocellis 2011). Some researchers fold TRP channels into an "extended" endocannabinoid system, though they sit apart from the core CB₁ and CB₂ receptors.
• Beyond the ECS entirely. CBG is also a potent agonist at α₂-adrenoceptors and an antagonist at 5-HT₁ₐ serotonin receptors (Cascio 2010), both of which belong to other signaling systems. Blood-pressure caution: because α₂-adrenoceptors help regulate blood pressure, anyone taking cardiovascular medication should be cautious and consult a clinician (Cascio 2010).

All of that was measured in receptors and cells, which is exactly what Demonstrated · in vitro means. Carrying it over to effects in people is a separate question with far less behind it. Animal work is the nearest step: in one mouse study, CBG reduced inflammation in an experimental model of colitis (Borrelli 2013). A preclinical signal, then, and not evidence of benefit in humans. Emerging

What is known, and what is not

So the map is good. The steering is another matter. The receptors, the two endocannabinoids and the enzymes that make and break them are Established. Most claims that a specific cannabinoid improves a health outcome through the ECS sit at Emerging or Hypothesized, promising in cells or animals and largely unconfirmed in people. Put the two side by side and the gap looks like this:

• Established. Settled physiology covers the ECS's components, their basic signaling, and the system's part in regulating appetite, pain, mood, sleep and immunity.
• Emerging / Hypothesized. Whether CBG or another phytocannabinoid reliably shifts those processes to a person's benefit is still an open question. For CBG, the human record is one small trial. Everything else is in vitro (Cascio 2010, De Petrocellis 2011) or in animals (Borrelli 2013).
• A named hypothesis, not a fact. Some researchers propose that low endocannabinoid activity, or "tone," underlies certain conditions, an idea sometimes called clinical endocannabinoid deficiency. It remains a research hypothesis, and nobody has shown it working as a mechanism. Hypothesized
• The ECS is only part of the picture. Some cannabinoid effects bypass the ECS entirely. CBG's antibacterial activity in the laboratory (Appendino 2008), for example, runs through a mechanism outside it, so treating "cannabinoid" and "ECS" as synonyms oversimplifies the science.

For anyone writing product copy, the line between those lists is the one to hold. The physiology of the ECS is settled; what a given product does to it is not. Where the science has not arrived, the topic carries Catalogue in progress and the gap stays open.

Common questions